FilingReader Intelligence
KPC Pharmaceuticals wins drug approval, declares dividend
July 21, 2025 at 05:10 PM UTC•By FilingReader AI
KPC Pharmaceuticals Inc. received drug registration approval for Sevelamer Carbonate oral suspension, a treatment for high phosphorus levels in chronic kidney disease patients.
The company also announced its 2024 annual cash dividend of 0.30 yuan per A-share, totaling 227 million yuan, with distribution scheduled for July 30, 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600422•Shanghai Stock Exchange
News Alerts
Get instant email alerts when KPC Pharmaceuticals Inc publishes news
Free account required • Unsubscribe anytime